Management of Opioid Use Disorder: See Practice Guideline 900.5034

Buprenorphine Patch (Butrans) is Formulary Restricted to continuation of PTA therapy

Subcutaneous buprenorphine extended‐release:

• • SUBLOCADE® is Restricted as below:
    • Ambulatory:  For clinics (typically primary care, Pain Clinics and Project Nurture); due to REMS program, only to be filled through Legacy Apothecary. 
    • Inpatient: Non-formulary
    • See Legacy Health REMS Requirements for detail.

• • BRIXADI® is Formulary Restricted as below:
    • Weekly Formulation is limited to outpatient clinics, PES (Psychiatric Emergency Services), and ESUDS (Emergency Substance Use Disorder Service), and LEMC Inpatient Pilot Program.
    • Monthly formulation will be limited to outpatient clinics and LEMC Inpatient Pilot Program
    • Planned transition to sublingual buprenorphine during inpatient stays.
    • The goal of the Brixadi REMS is to mitigate the risk of serious harm or death that could result from intravenous self-administration, and includes health care setting, pharmacy and wholesaler-distributor requirements for dispensing.
    • See Legacy Health REMS Requirements for detail.

• Micromedex
• CareNotes
• UpToDate
• Facts & Comparisons
• MedLinePlus (Patient Information)